Match Document Document Title
5905072 Adjuvants for systemic fungicides, fungicidal compositions which contain them and their use  
Adjuvants for systemic fungicides in the form of a stable microemulsion comprise water, a mixture of methyl esters of fatty acids obtained by the transesterification of vegetable oils, an anionic...
5902815 Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction  
This invention relates to a new method for treating or preventing brain damage caused by NMDA receptor hypofunction (NR/hypo), using drugs such as lisuride which stimulate (agonize) activity at the...
5902808 Methods and compositions for controlling biofouling using N-alkyl heterocyclic compounds  
The present invention relates to a method to inhibit bacteria from adhering to a submergible surface. The method contacts the submergible surface with an effective amount of at least one N-alkyl...
5886051 Methods and compositions for the treatment of neurodegeneration  
Methods and pharmaceutical compositions in unit dosage form for treating neurodegeneration in a human or non-human animal afflicted therewith wherein the active agent is a therapeutically effective...
5877182 Piperidines promote release of growth hormone  
The present invention is directed to certain piperidines, pyrrolidines, and hexahydro-1H-azepines of the general structural formula: ##STR1## wherein B is selected from: ##STR2## and R 1 , R 1a , R...
5877186 Carotenoid synthesis inhibiting herbicides and fatty acid synthesis inhibiting oxime herbicides as anti-apicomplexa protozoan parasite agents  
Protozoan parasites of the phylum Apicomplexa include some of the most important causative agents of human and animal diseases, in particular, malaria. The discovery that an organelle found inside...
5872117 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same  
This invention relates to a 1,2-ethanediol derivative and a salt thereof, a process for producing the same, and a cerebral function-improving agent comprising the same. The cerebral...
5869024 Methods and compositions for using non-ionic contrast agents to reduce the risk of clot formation in diagnostic procedures  
In accordance with the present invention a novel method and composition for using nonionic contrast media to reduce the risk of clot formation in a diagnostic procedure is disclosed. Novel...
5869067 Bi-aromatic compounds and pharmaceutical and cosmetic compositions  
The present invention relates to new aromatic compounds, to their preparation and to their use in human and veterinary medicine and in cosmetic compositions.
5866601 Carbocyclic compounds  
Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane...
5863903 Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes  
The present invention relates to hydroxy alkyl piperidine compounds and pharmaceutical compositions thereof which can be used to treat diabetes.
5859027 Antimicrobial agent  
The invention provides a method of treating a fungal infection comprising administering to an animal having a fungal infection a composition comprising an infection treating effective amount of a...
5859017 Method for inhibiting mast cell and basophil activation  
In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is...
5856309 Amidinopyrroline derivatives, processes for their production and pharmaceutical agents containing these compounds  
Compound of formula (I) are disclosed ##STR1## as well as optically active isomers or pharmacologically acceptable salts thereof. The compounds are useful active ingredients in pharmaceutical...
5854268 Azetidine, pyrrolidine and piperidine derivatives  
A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT 1 -like receptors, being potent agonists of the human 5-HT 1D α receptor subtype whilst...
5849737 Compositions and methods for treating pain  
Compositions and methods for alleviating pain (in particular, neuropathic pain) in a mammalian patient, wherein an effective amount of a physiologically-acceptable salt of a compound of the general...
5846980 N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants  
The invention relates to substituted nitrogenous heterocycles derivatives of general formula (I) ##STR1## in the racemic or optically pure form and/or in the form of cis/trans isomers, their...
5840734 Use of tempol in the prevention of photoaging  
A method of preventing photoaging and other types of sun damage by topically applying a composition containing Tempol is provided. Pharmaceutical compositions comprising Tempol for the prevention...
5840759 Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents  
The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric...
5837703 Amino-alcohol substituted cyclic compounds  
Therapeutic compounds have the formula: (X)j-(core moiety), j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or...
5837736 Nitric oxide-releasing compounds to sensitive cancerous cells to chemotherapeutic agents  
The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric...
5834508 Ketone derivatives  
A novel ketone derivative (I) which possesses a potent inhibitory activity against thiol protease such as papain, cathepsin B, cathepsin H, cathepsin L, calpain or the like with excellent...
5834465 Treatment with combined NMDA and non-NMDA antagonists to reduce excitotoxic CNS damage  
This invention involves a pharmaceutical mixture for preventing or reducing excitotoxic brain damage caused by hypoxia/ischemia (such as stroke) and various other factors. This mixture comprises an...
5834486 Piperidinyl-2-alkyl, substituted linear polyamines for the reduction of intracellular, endogenic polyamine levels such as putrescine, spermidine and spermine, and their impact on cell proliferation  
The invention relates to compounds of formula (I) ##STR1## wherein either R 1 is hydrogen and R 2 is lower alkyl lower alkenyl or lower alkynyl, m is 3 or 4 and n is 2 or 3; or R 1 ...
5827852 Coated pharmaceutical compositions  
Pharmaceutical composition suitable for coating comprising a composition for oral administration in unit dosage form wherein said composition has been coated with from about 0.01% to about 10% by...
5824650 Topical composition containing a substance P antagoinst  
The invention relates to a therapeutic composition for topical application containing at least one product with an irritant side effect and a substance P antagonist for reducing or even eliminating...
5821261 Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase  
Disclosed herein are compounds of Formula (I) ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and...
5814656 Selective prevention of organ injury is sepsis and shock using selective release of nitric oxide vulnerable organs  
A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically...
5814667 Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers  
The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric...
5811005 Apparatus for intravenous administration of solutions of cell-free hemoglobin including a nitroxide bound to a matrix  
An apparatus for intravenous administration of solutions of cell-free hemoglobin is disclosed. The apparatus includes a solution of cell-free hemoglobin in fluid connection with a housing having an...
5801181 Amino alcohol substituted cyclic compounds  
Therapeutic compounds have the formula: (X)j--(core moiety), J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture,...
5801185 Method of treating Tay-Sachs disease  
A method is disclosed for the treatment of Tay-Sachs disease comprising subjecting said cells to a glycolipid inhibitory effective amount of an N-alkyl derivative of...
5798366 Method for treatment of CNS-involved lysosomal storage diseases  
A method is disclosed for the in vivo treatment of patients having a lysosomal storage disease with a significant central nervous system (CNS) involvement. Said method comprises administration to...
5795907 Gastin and CCK receptor ligands  
Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R 1 (m) represents up to 6 substituents, K represents --O--, --S--, --CH 2...
5789404 3-substituted 1-arylindole compounds  
3-Substituted 1-arylindole compounds are provided having general formula (I) ##STR1## wherein Ar is an optionally substituted aryl group; X represents a divalent hydrocarbon group, methyleneoxy or...
5786369 Method of inhibiting the surface expression of glycolipid receptors for bacteria  
A method is disclosed for inhibiting the surface expression of glycolipid receptors for bacteria by subjecting bacteria cells to an inhibitory effective amount of an N-alkyl derivative of...
5783563 Method for treatment or prophylaxis of venous thrombosis  
A method is disclosed for treatment or prophylaxis of venous thrombosis employing the peptide HOOC--CH 2 --(R)Cgl--aze--Pab or a stereoisomer thereof or a physiologically acceptable salt thereof.
5767130 Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists  
This invention discloses that kainic acid receptor antagonists (KA antagonists) can act as "safener" agents to reduce or prevent adverse side effects caused by NMDA antagonists. NMDA antagonists...
5767118 4-Heterocyclic peperidines promote release of growth hormone  
The present invention is directed to certain novel compounds identified as 4-heterocycle substituted piperidines of the general structural formula: ##STR1## wherein R 1 , R 4 , R 5 , A, R 3 and...
5767151 3,3-(disubstituted) cyclohexan-1-ylidine acetate dimers and related compounds  
The present invention relates to novel 3,3-(disubstituted)-cyclohexan-1-ylidene acetate dimers of Formula (I): ##STR1## and related compounds, pharmaceutical compositions containing these...
5763476 Sublingual or buccal pharmaceutical composition  
The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz 2,3:6,7!oxepino- 4 ,5-c!pyrrole or a pharmaceutically...
5750528 Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease  
Compounds which block neuronal M-channels are useful for treating conditions involving neurotransmitter deficiencies, traumatic brain injury, or the depressive phase of bipolar disorder. Compounds...
5744485 Carbamates and ureas as modifiers of multi-drug resistance  
The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical...
5741799 Heterocyclic thrombin inhibitors  
Heterocyclic thrombin inhibitors are provided which have the structure ##STR1## wherein n, R, R 1 , R 2 , R 3 , G, G x , R 6 ', Ra, Xa, R 6 , Rb, R 3 , p, Q, A and R 4 are as defined herein.
5733900 Percutaneous administration base composition and percutaneous administration medicinal composition comprising said base composition and medicine  
A percutaneous administration base composition is disclosed comprising an absorption promoter, a moisture-retaining agent, water, an irritation-lessening agent, a lower alcohol and an organic acid...
5731309 Substituted heteroalkyleneamine neurokinin antagonists  
Compounds of formula I ##STR1## wherein Q 1 , Q 2 , Q 3 , and Q 4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide...
5728714 Method for treating hair loss using tempo  
A method for ameliorating a cellular dysfunction of a tissue such as the cosmetic treatment of hair loss and stimulation of hair growth is disclosed. The method comprises administering substituted...
5726184 Tetralin compounds with improved MDR activity  
The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical...
5719141 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide derivatives  
Compounds of the formula I ##STR1## in which R 1 is arylamino, N-aryl-N-(lower alkoxy-lower alkyl)-amino, N-aryl-N-aryl-lower alkyl-amino or heterocyclyl bonded via a ring carbon atom, X is a...
5700830 Use of nitric oxide-releasing agents for reducing metastasis risk  
A method for inhibiting the adherence between cancerous cells and noncancerous structures in a mammal, comprising the administration to the mammal of a nitric oxide-releasing compound containing a...